Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: A population-based study

Diabetes

Volumn 52, Issue 2, 2003, Pages 442-447

  Engström, Gunnar ^a   Stavenow, Lars ^a   Hedblad, Bo ^a   Lind, Peter ^a   Eriksson, Karl Fredrik ^a   Janzon, Lars ^a   Lindgärde, Folke ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; CERULOPLASMIN; FIBRINOGEN; HAPTOGLOBIN; OROSOMUCOID; PLASMA PROTEIN;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; HEART INFARCTION; HUMAN; INCIDENCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STROKE;

BLOOD PRESSURE; BLOOD PROTEINS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHOLESTEROL; COHORT STUDIES; CREATININE; DIABETES COMPLICATIONS; DIABETES MELLITUS; HEART DISEASES; HUMANS; INCIDENCE; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREVALENCE; RISK FACTORS; SMOKING; SWEDEN; TRIGLYCERIDES;

EID: 0037312855     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.2.442     Document Type: Article

References (43)

1. Ganrot PO, Gydell K, Ekelund H: Serum concentration of α2-macroglobulin, haptoglobin and α1-antitrypsin in diabetes mellitus. Acta Endocrinol (Copenh) 55:537-544, 1967
2. McMillan DE: Increased levels of acute-phase serum proteins in diabetes. Metabolism 38:1042-1046, 1989
3. Daimon M, Susa S, Yamatani K, Manaka H, Hama K, Kimura M, Ohnuma H, Kato T: Hyperglycemia is a factor for an increase in serum ceruloplasmin in type 2 diabetes. Diabetes Care 21:1525-1528, 1998
4. Pickup JC, Crook MA: Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241-1248, 1998
5. Ford ES: Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 22:1971-1977, 1999
6. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD: von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 19:3071-3078, 1999
7. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51:1131-1137, 2002
8. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G: Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities Study): a cohort study. Lancet 353:1649-1652, 1999
9. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334, 2001
10. Ford ES: Leukocyte count, erythrocyte sedimentation rate, and diabetes incidence in a national sample of US adults. Am J Epidemiol 155:57-64, 2002
11. Hotamisligil GS: The role of TNF-α and TNF receptors in obesity and insulin resistance. J Intern Med 245:621-625, 1999
12. Nilsson J, Jovinge S, Niemann A, Reneland R, Lithell H: Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 18:1199-1202, 1998
13. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972-978, 1999
14. Lind P, Hedblad B, Stavenow L, Janzon L, Eriksson KF, Lindgärde F: Influence of plasma fibrinogen levels on the incidence of myocardial infarction and death is modified by other inflammation-sensitive proteins: a long-term cohort study. Arterioscler Thromb Vasc Biol 21:452-458, 2001
15. Engström G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgärde F: Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation 105:2632-2637, 2002
16. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-979, 1997
17. Ernst E, Koenig W: Fibrinogen and cardiovascular risk. Vasc Med 2:115-125, 1997
18. Vilbergsson S, Sigurdsson G, Sigvaldason H, Sigfusson N: Coronary heart disease mortality amongst non-insulin-dependent diabetic subjects in Iceland: the independent effect of diabetes: the Reykjavik Study 17-year follow up. J Intern Med 244:309-316, 1998
19. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287:2570-2581, 2002
20. Kannel WB, D'Agostino RB, Wilson PW, Belanger AJ, Gagnon DR: Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 120:672-676, 1990
21. Berglund G, Nilsson P, Eriksson KF, Nilsson JÅ, Hedblad B, Kristenson H, Lindgärde F: Long-term outcome of the Malmö Preventive Project: mortality and cardiovascular morbidity. J Intern Med 247:19-29, 2000
22. Eriksson KF, Lindgärde F: Impaired glucose tolerance in a middle-aged male urban population: a new approach for identifying high-risk cases. Diabetologia 33:526-531, 1990
23. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197, 1997
24. Thorell JI, Larson SM: Radioimmunoassay and Related Techniques. St. Louis, MO, CV Moseby, 1978, p. 205-211
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28:412-419, 1985
26. Laurell CB: Electroimmuno assay. Scand J Clin Lab Invest Suppl 124:21-37, 1972
27. Engström G, Berglund G, Göransson M, Hansen O, Hedblad B, Merlo J, Tydén P, Janzon L: Distribution and determinants of ischaemic heart disease in an urban population: a study from the myocardial infarction register in Malmö, Sweden. J Intern Med 247:588-596, 2000
28. Engström G, Jerntorp I, Pessah-Rasmussen H, Hedblad B, Berglund G, Janzon L: Geographical distribution of stroke in an urban population: relationships with prevalence of risk factors and socioeconomic circumstances. Stroke 32:1098-1103, 2001
29. Ganda OP, Arkin CF: Hyperfibrinogenemia: an important risk factor for vascular complications in diabetes. Diabetes Care 15:1245-1250, 1992
30. Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG: Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med 133:81-91, 2000
31. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH: Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51:1157-1165, 2002
32. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD: C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arterioscler Thromb Vasc Biol 22:593-598, 2002
33. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344:2016-2018, 2001
34. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 340:115-126, 1999
35. Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48:1-9, 1999
36. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D: Cellular receptors for advanced glycation end products: implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 14:1521-1528, 1994
37. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820, 2001
38. Perticone F, Ceravolo R, Candigliota M, Ventura G, Iacopino S, Sinopoli F, Mattioli PL: Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes 50:159-165, 2001
39. Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T: Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 83:2907-2910, 1998
40. Duncan BB, Schmidt MI, Chambless LE, Folsom AR, Carpenter M, Heiss G: Fibrinogen, other putative markers of inflammation, and weight gain in middle-aged adults: the ARIC study. Obes Res 8:279-286, 2000
41. Östenson CG: The pathophysiology of type 2 diabetes mellitus: an overview. Acta Physiol Scand 171:241-247, 2001
42. Arner P, Pollare T, Lithell H: Different aetiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects. Diabetologia 34:483-487, 1991
43. Hedblad B, Nilsson P, Janzon L, Berglund G: Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects: results from a cross-sectional study in Malmö, Sweden. Diabet Med 17:299-307, 2000